New pill aims to shrink spleen in bone marrow cancer
NCT ID NCT07317700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. The study compares flonoltinib to an existing drug, ruxolitinib, to see if it can reduce spleen size and improve symptoms. About 105 participants will take the drug daily until they meet withdrawal criteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Flonoltinib maleate tablets
What this could lead to
If successful, flonoltinib could offer a new treatment option for myelofibrosis, potentially reducing spleen size and easing symptoms.
What could go wrong
This is a phase 3 trial, but it's still early to know if flonoltinib works better than existing drugs. Side effects are possible, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITINGTianjin, Tianjin Municipality, 300052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••